Benefits of polyunsaturated fatty acid (PUFA) supplementation in therapy of children and teenagers with Asperger’s Syndrome

INTERVENTION: Post randomization, the patients will be receive polyunsaturated fatty acid (n=25) or placebo (n=25) capsules for 3 months. This will be followed by a switch over of the placebo group to PUFA and further intervention for another 3 months. Clinical symptoms and blood fatty acid status will be assessed at baseline and at two time points (3 and 6 months) during the intervention period. CONDITION: Asperger's syndrome ; Mental and Behavioural Disorders ; Asperger's syndrome PRIMARY OUTCOME: 1. To evaluate the possible benefits of PUFA supplementation in patients with Asperger?s syndrome and autistic 'well functioning' children and teenagers with normal intelligence index and well‐developed speaking abilities.; 2. Changes in the core clinical symptoms pertaining to behavior and learning will be assessed by Conners Parent Rating Scales, psychiatric examination and questionnaire of symptoms, discussion with parents, based on ICD‐10, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV), Australian Scale for Asperger?s Syndrome of M.S. Garnett and A.J. Atwood, Asperger Syndrome Diagnostic Interview (ASDI) developed by the investigator. SECONDARY OUTCOME: To prepare initial indications to supplement subjects with Asperger?s syndrome and autistic 'well functioning' children and teenagers with PUFA, based on psychiatric and psychological evaluation, and blood tests. INCLUSION CRITERIA: 1. Diagnosis of Asperger?s syndrome according to ICD‐10 (normal IQ) 2. Age 6 ? 19 years